Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo
批准号:
10403499
负责人:
JOSEPH Mark METZGER
金额:
$46.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2024-04-30
关键词:
AcuteAgeCardiacChemical EngineeringChemicalsClinical TreatmentClinical TrialsDNA Sequence AlterationDataDefectDiseaseDisease OutcomeDisease ProgressionDissectionDuchenne muscular dystrophyExonsFailureFoundationsGenesGeneticGoalsHealthImmunosuppressionInvestigationLesionLifeLimb structureLinkMembraneModelingMolecularMuscleMuscular AtrophyMuscular DystrophiesMutationMyocardiumNonsense MutationOxidative StressPathway interactionsPatientsPharmacodynamicsPhysiologicalProgressive DiseaseRespiratory MusclesSarcolemmaSkeletal MuscleStriated MusclesStructureTeenagersTestingTherapeuticTimeTreatment EfficacyUnited States National Institutes of HealthWheelchairsbaseboysclinical applicationcopolymerdesigneffective therapyin vivoinsightmitochondrial dysfunctionnovelnovel strategiesnovel therapeuticspreclinical studypreservationprotective effectpublic health relevancerespiratoryskeletal muscle wasting
中文摘要
摘要
Duchenne肌营养不良症(DMD)是一种毁灭性的、普遍致命的X连锁隐性遗传病
进行性横纹肌退化。DMD男孩在生命早期就有严重的骨骼肌萎缩,他们
通常是10-12岁的轮椅。DMD在十几岁到二十五岁左右是致命的,原因是心肌
和呼吸肌衰竭。这些严峻的现实突显了发现和发现
实施新的方法和疗法,可能会影响DMD的疾病进展和结局。
这项建议对美国国立卫生研究院的意义是巨大的。没有治愈DMD的方法,也没有任何有效的临床治疗方法
可以阻止或逆转疾病的治疗。这款应用程序具有突出的健康意义和
专注于一流的合成膜稳定剂的影响,这些稳定剂直接针对主要生理
DMD的缺陷:严重的肌膜不稳定。膜稳定剂可显著保护
营养不良的心肌,然而,到目前为止,营养不良的骨骼肌没有得到明显的保护,
缓和了DMD领域对这门课的热情。现在,据我们所知,我们第一次发现
药效学优化的膜稳定剂对营养不良肢体有显著的保护作用
活体中的骨骼肌。这一潜在的治疗突破对NIH作为一种新的
治疗营养不良横纹肌的可行方法。指导这一提议的首要假设是
合成嵌段共聚物的力学导引结构-功能分析将揭示新的基本原理
对膜稳定如何保护肌肉的细胞学基础的见解。这些机械导引
研究具有巨大的潜在影响,因为它们为寻求有效的最终目标提供了必要的基础
对体内营养不良横纹肌的长期保护作用。
英文摘要
Abstract
Duchenne muscular dystrophy (DMD) is a devastating and universally fatal X-linked recessive disease of
progressive striated muscle deterioration. DMD boys have severe skeletal muscle wasting early in life and they
are typically wheelchair bound by age 10-12. DMD is fatal by the late teens to mid-twenties due to cardiac muscle
and respiratory muscle failure. These grim realities underscore the tremendous urgency to discover and
implement new approaches and therapies that could impact disease progression and outcomes in DMD.
Significance of this proposal to the NIH is tremendous. There is no cure for DMD, or any effective clinical
treatment that can halt or reverse the disease. This application derives outstanding health significance and
impact by focusing on first-in-class synthetic membrane stabilizers that directly target the primary physiological
defect in DMD: severe muscle membrane instability. Membrane stabilizers confer marked protection to
dystrophic cardiac muscle, however, until now, dystrophic skeletal muscles were not significantly protected,
tempering enthusiasm in the DMD field for this class of therapy. Now, for the first time to our knowledge, we find
that pharmacodynamically optimized membrane stabilizers have a dramatic protective effect in dystrophic limb
skeletal muscles in vivo. This potential therapeutic breakthrough has great significance to the NIH as a new
viable approach to treat dystrophic striated muscles. The overarching hypothesis directing this proposal is that
mechanistically guided structure-function analysis of synthetic block copolymers will illuminate new fundamental
insights into the cellular basis of how membrane stabilization protect muscles. These mechanistically guided
studies have great potential impact as they serve the required foundation in seeking the ultimate goal of effective
long-term protection to dystrophic striated muscles in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inclusive Excellence Training Program in the Systems Biology of Cardiovascular Inflammation
-
批准号:10555753
-
项目类别:
-
资助金额:$20.62万
-
财政年份:2023
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Skeletal muscle sarcomere function in health and disease
-
批准号:10445504
-
项目类别:
-
资助金额:$54.4万
-
财政年份:2022
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Skeletal muscle sarcomere function in health and disease
-
批准号:10655541
-
项目类别:
-
资助金额:$53.11万
-
财政年份:2022
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo
-
批准号:10153697
-
项目类别:
-
资助金额:$45.23万
-
财政年份:2018
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo
-
批准号:9923445
-
项目类别:
-
资助金额:$46.63万
-
财政年份:2018
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin and Heart Disease
-
批准号:9367436
-
项目类别:
-
资助金额:$38.08万
-
财政年份:2017
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Myofilaments as regulators of heart function in disease
-
批准号:10364296
-
项目类别:
-
资助金额:$55.14万
-
财政年份:2017
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Myofilaments as regulators of heart function in disease
-
批准号:9902505
-
项目类别:
-
资助金额:$38.31万
-
财政年份:2017
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Myofilaments as regulators of heart function in disease
-
批准号:9311335
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2017
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Myofilaments as regulators of heart function in disease
-
批准号:10544034
-
项目类别:
-
资助金额:$55.36万
-
财政年份:2017
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Targeted membrane integrity in cardiac ischemia and reperfusion
-
批准号:10421054
-
项目类别:
-
资助金额:$63.23万
-
财政年份:2014
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Targeted membrane integrity in cardiac ischemia and reperfusion
-
批准号:8962165
-
项目类别:
-
资助金额:$65.45万
-
财政年份:2014
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Targeted membrane integrity in cardiac ischemia and reperfusion
-
批准号:9180719
-
项目类别:
-
资助金额:$65.45万
-
财政年份:2014
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Targeted membrane integrity in cardiac ischemia and reperfusion
-
批准号:9976559
-
项目类别:
-
资助金额:$63.23万
-
财政年份:2014
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin Function in Aging Heart
-
批准号:8659327
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2010
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin Function in Aging Heart
-
批准号:7886262
-
项目类别:
-
资助金额:$34.81万
-
财政年份:2010
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin Function in Aging Heart
-
批准号:8061648
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2010
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin Function in Aging Heart
-
批准号:8236955
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2010
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Dystrophin Function in Aging Heart
-
批准号:8437208
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2010
-
负责人:JOSEPH Mark METZGER
-
依托单位:
Administrative Leadership Core
-
批准号:7499377
-
项目类别:
-
资助金额:$5.82万
-
财政年份:2007
-
负责人:JOSEPH Mark METZGER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: